Synapse - Works

Results (2146)

Sensitivity of HER2-low uterine carcinosarcoma organoids to the antibody-drug conjugate, trastuzumab deruxtecan

Meeting Abstract

Moufarrij, S.; Dopeso, H.; Green, H.; Gill, K.; Brown, D.; Zammarrelli, W.; Varice, N.; Wu, M.; Paula, A. D.; de Oliveira, T. B.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Final overall survival data from a randomized, open-label, phase II study of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel among patients with recurrent platinum-resistant ovarian cancer

Meeting Abstract

Colombo, N.; Van Gorp, T.; Matulonis, U.; Oaknin, A.; Grisham, R.; Provencher, D.; Fleming, G.; Olawaiye, A.; Pashova, H.; Tudor, I. C.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation

Meeting Abstract

Schram, A.; Shapiro, G.; Thompson, J.; Vandross, A.; Kummar, S.; El-Khoueiry, A.; LeDuke, K.; Fellous, M.; Alland, L.; Dumbrava, E.
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study

Meeting Abstract

Marth, C.; Moore, R.; Bidzinski, M.; Pignata, S.; Ayhan, A.; Rubio, M. J.; Beiner, M.; Hall, M.; Vulsteke, C.; Braicu, E. I.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial

Meeting Abstract

Harter, P.; Wimberger, P.; Okamoto, A.; Reuss, A.; Lim, M. C.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Trédan, O.; Hietanen, S.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Mainstreaming in gynecologic oncology clinics triples the odds of genetic testing among patients with epithelial ovarian cancer

Meeting Abstract

Sia, T.; Byrne, M.; Fong, C.; Khurram, A.; Zhou, Q.; Saban, S.; Wu, M.; Varice, N.; Hamilton, J.; Carrot Zhang, J.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Progression-free and overall survival in newly-diagnosed homologous recombination DNA-repair deficient ovarian cancer without a BRCA mutation

Meeting Abstract

Graves, S.; Sullivan, M.; Adkoli, A.; Zhou, Q.; Chi, D.; Ellenson, L.; O'Cearbhaill, R.; Weigelt, B.; Grisham, R.
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/ RAMP 201 Part A

Meeting Abstract

Banerjee, S.; Van Nieuwenhuysen, E.; Santin, A.; Ring, K.; Colombo, N.; Thaker, P.; Prendergast, E.; Clamp, A.; Ray-Coquard, I.; Chon, H. S.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)

Meeting Abstract

Schram, A.; Eskander, R.; Sill, M.; Hagemann, A.; Waggoner, S.; Press, J.; Ghamande, S.; Zivanovic, O.; Bottsford-Miller, J.; Aghajanian, C.
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial

Meeting Abstract

Eskander, R.; Sill, M.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M.; Cantuaria, G.; Girda, E.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save